April 8 (Reuters) – Staff reviewers from the U.S. Food and Drug Administration on Friday questioned if Clovis Oncology Inc’s lung cancer drug was more effective than available treatments.
The post FDA staff questions Clovis drug’s efficacy over current treatments appeared first on NASDAQ.